Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
Appointed director
CC transcript
CATALYST BIOSCIENCES, INC. (CBIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Unaudited interim condensed consolidated financial statements of Beijing Continent as of and for the six months ended June 30, 2023"
07/24/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/20/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
07/12/2023 PRER14A Form PRER14A - Preliminary Proxy Soliciting materials:
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/05/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/05/2023 8-K Quarterly results
03/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/21/2023 8-K Quarterly results
03/02/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/02/2023 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "ASSET PURCHASE AGREEMENT",
"CATALYST AND GNI URGE INVESTORS AND STOCKHOLDERS TO READ THESE MATERIALS CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT CATALYST, GNI, THE GNI TRANSACTIONS AND RELATED MATTERS."
02/14/2023 SC 13G/A Nantahala Capital Management, LLC reports a 1.4% stake in Catalyst Biosciences, Inc.
02/14/2023 SC 13G/A ORBIMED ADVISORS LLC reports a 0% stake in Catalyst Biosciences, Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/05/2023 3 Eastling Thomas Wilson (Director) has filed a Form 3 on CATALYST BIOSCIENCES, INC.
01/05/2023 3 GNI Group Ltd. (10% Owner) has filed a Form 3 on CATALYST BIOSCIENCES, INC.
01/05/2023 3 Luo Ying (Director) has filed a Form 3 on CATALYST BIOSCIENCES, INC.
12/27/2022 425 Form 425 - Prospectuses and communications, business combinations:
12/27/2022 8-K Investor presentation
Docs: "by and among CATALYST BIOSCIENCES, INC., as the Buyer, and GNI GROUP LTD., and GNI HONG KONG LIMITED, as the Sellers Dated as of December 26, 2022",
"BUSINESS COMBINATION AGREEMENT",
"Certificate of Designation of Series X Convertible Preferred Stock",
"Amended and Restated Bylaws of Catalyst Biosciences, Inc",
"“Agreement”) is made and entered into as of [date] between Catalyst Biosciences, Inc., a Delaware corporation , and [name of director], a director, officer or member of the executive committee of the Company (“Indemnitee”",
"Acquires F351, a Phase 3 Drug to Treat Fibrosis Will Acquire Controlling Interest in Continent, a China-Based Commercial Pharma Company, from the GNI Group in Subsequent Transaction",
"Presentation for investor conference call held by Catalyst Biosciences, Inc. on December 27, 2022"
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/04/2022 8-K Quarterly results
10/07/2022 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
09/22/2022 SC 13D/A JEC II Associates, LLC reports a 0% stake in Catalyst Biosciences, Inc.
08/25/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
08/19/2022 SC 13D/A SINGER JULIAN D. reports a 7.1% stake in Catalyst Biosciences, Inc.
08/19/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/15/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 DFAN14A Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy